Polysaccharide dry-mouth pastille,
does it really help with Increased salivary flow and relief of dry mouth?
research showsThe grade is C with 50 points. In a 26-person crossover trial, ten-minute salivary-flow change was 8.03±3.66 g with the pastille versus 3.71±2.45 g with Parafilm control, P<0.0001. Dividing the 4.32-g difference by the pooled treatment-period standard deviation gives an approximate standardized difference of 1.39. The primary endpoint was a short-term physiological measure, however, and the only trial was an open-label, manufacturer-designed single-center study.
ads claimIt is fair to say that sucking and chewing this tested pastille produced more saliva over ten minutes. That does not prove all-day or durable treatment of xerostomia, and products with different ingredients or doses should not inherit this result.
Useful facts when choosing a product
- The tested pastille contained gum arabic, hydroxyethylcellulose, sodium hyaluronate, and carrageenan and was sucked and chewed for up to five minutes.
- Ten-minute flow change was 8.03±3.66 g with the pastille and 3.71±2.45 g with Parafilm.
- The trial tested one ipalat Hydro Med formulation; equivalence to Korean-market products was not established.
What the research actually shows
The 2021 randomized-sequence crossover trial by Bielfeldt S, Wilhelm D, Neumeister C, Schwantes U, and Wilhelm KP had all 26 participants use the pastille and a 5×5-cm Parafilm M control. In the 26-person full analysis set, flow rose from 2.03±1.40 to 10.06±4.14 g/10 min with the pastille and from 2.13±1.36 to 5.85±3.27 with control. A confidence interval was not reported. DRKS00017393 prespecified ten-minute total salivary flow but did not report allocation concealment or sequence generation. Dr. Pfleger Arzneimittel GmbH co-designed and funded the study, and two authors, Neumeister C and Schwantes U, were company employees.
Why this is classified as C (50)
The primary physiological effect was large and statistically clear, but evidence was limited to a 26-person open single-dose manufacturer trial using a surrogate endpoint, giving C with 50 points.
Counterpoint. Applicability to near-absent salivary function or xerostomia caused by medication, radiotherapy, or Sjögren disease requires separate evidence.
Rejudgment record. Cross-check applied — Cross-checked the article and DRKS record for the prespecified primary endpoint, 26-person analysis, means and standard deviations, open-label design, completer-analysis plan, unreported concealment, and manufacturer design and funding
| Endpoint | S | Surrogate marker - laboratory or imaging measures |
| Replication | R1 | Single confirmatory trial |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E+ | Meets the clinically important threshold |
The scoring table and the verdict agree (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Increased ten-minute salivary flow | C | Change was 8.03 versus 3.71 g/10 min in 26 participants. |
| Short-term dry-mouth relief | C | The secondary VAS was -19.9 versus -3.3 mm, but this was a single-dose assessment. |
| Durable xerostomia treatment | ? | The trial did not measure durability beyond the acute assessment. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Bielfeldt S, Wilhelm D, Neumeister C, Schwantes U, Wilhelm KP. 2021 | Single-center open-label randomized-sequence crossover controlled trial | 26 | Funded and co-designed by Dr. Pfleger Arzneimittel GmbH; two authors, Neumeister C and Schwantes U, were company employees | Prespecified change in ten-minute salivary flow | 8.03±3.66 versus 3.71±2.45 g/10 min, P<0.0001; approximate standardized difference 1.39; no 95% CI reported | Large short-term physiological effect limited by surrogate status, open design, tiny size, and manufacturer-only evidence |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-08-15).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-15 · Corrections: none
Cite this verdict
[Chamgap] Polysaccharide dry-mouth pastille x salivary flow and dry-mouth relief — Evidence Grade C·50. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/general/polysaccharide-dry-mouth-pastille-salivary-flow/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.